Drug Discovery and Development of Recently Approved Drugs: Tisotumab Vedotin

Research Article
Open access

Drug Discovery and Development of Recently Approved Drugs: Tisotumab Vedotin

Hongzhu Long 1 , Boxuan Ma 2* , Mingyu Shi 3 , Xuetong Zeng 4
  • 1 Cheltenham Ladies’ College, Bayshill Rd, Cheltenham, United Kingdom    
  • 2 University of California, Santa Cruz, Santa Cruz, CA, United States    
  • 3 St George’s School Cologne, Duisburg, Germany    
  • 4 Shenzhen Foreign Language School, Shenzhen, China    
  • *corresponding author bma79@ucsc.edu
Published on 28 April 2023 | https://doi.org/10.54254/2753-8818/4/20220526
TNS Vol.4
ISSN (Print): 2753-8826
ISSN (Online): 2753-8818
ISBN (Print): 978-1-915371-27-0
ISBN (Online): 978-1-915371-28-7

Abstract

Recurrent or metastatic cervical cancer is the primary reason for dying in the female population. Although advanced research in immunization may provide a potential treatment for cervical cancer, it is still one of the usual fetal female cancers globally. Previous studies on bevacizumab and chemotherapy provided efficient treatments with a survival benefit for women, but different strategies are needed to increase the overall survival rate of this cancer. Tisotumab vedotin is an investigative and pioneering immunoglobulin-medicine combination that targets tissue factor (TF), a protein in high concentrations in various solid tumours. Tisotumab vedotin bonds to tissue factor on aimed cells and then releases monomethyl auristatin E (MMAE). In addition, Tisotumab vedotin’s direct cytotoxicity may increase nearby tumour cells’ spectator toxicity and various immune-linked effects. This paper will discuss previous studies on Tisotumab vedotin, and their data will be analyzed further. The improvement toward this treatment will be proposed as well. This paper aimed to establish a thorough understanding and further analysis of the previous clinical trials and findings on Tisotumab vedotin.

Keywords:

Cervical Cancer, Tisotumab vedotin, clinical trials

Long,H.;Ma,B.;Shi,M.;Zeng,X. (2023). Drug Discovery and Development of Recently Approved Drugs: Tisotumab Vedotin. Theoretical and Natural Science,4,89-95.
Export citation

References

[1]. McLachlan, J. et al. The Impact of Systemic Therapy Beyond First-line Treatment for Advanced Cervical Cancer. Clin. Oncol. 29, 153–160 (2017).

[2]. Hong, D. S. et al. Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer. Clin. Cancer Res. 26, 1220–1228 (2020).

[3]. Boussios, S. et al. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review. Crit. Rev. Oncol. Hematol. 108, 164–174 (2016).

[4]. Improved Survival with Bevacizumab in Advanced Cervical Cancer - PMC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010094/

[5]. Zamorano, A. S., Wan, L., Powell, M. A. & Massad, L. S. Repeating platinum/bevacizumab in recurrent or progressive cervical cancer yields marginal survival benefits. Gynecol. Oncol. Rep. 22, 48–51 (2017).

[6]. Eskander, R. N. & Tewari, K. S. Targeting angiogenesis in advanced cervical cancer. Ther. Adv. Med. Oncol. 6, 280–292 (2014).

[7]. Seagen Inc. A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer. https://clinicaltrials.gov/ct2/show/NCT03438396 (2022).

[8]. de Bono, J. S., Concin, N., Hong, D. S., Thistlethwaite, F. C., Machiels, J.-P., Arkenau, H.-T., Plummer, R., Jones, R. H., Nielsen, D., Windfeld, K., Ghatta, S., Slomovitz, B. M., Spicer, J. F., Yachnin, J., Ang, J. E., Mau-Sørensen, P. M., Forster, M. D., Collins, D., Dean, E., … Lassen, U. (2019). TISOTUMAB vedotin in patients with advanced or metastatic solid tumours (innovatv 201): A first-in-human, multicentre, phase 1–2 trial. The Lancet Oncology, 20(3), 383–393.

[9]. X, Z. et al. Expression of tissue factor in human cervical carcinoma tissue. Exp. Ther. Med. 16, (2018).

[10]. Tisotumab vedotin.Browsing drugs: Drugbank online. Browsing Drugs | DrugBank Online. (n.d.). Retrieved August 24, 2022, from https://go.drugbank.com/drugs

[11]. Breij, E. C. W., de Goeij, B. E. C. G., Verploegen, S., Schuurhuis, D. H., Amirkhosravi, A., Francis, J., Miller, V. B., Houtkamp, M., Bleeker, W. K., Satijn, D., & Parren, P. W. H. I. (2014). An antibody–drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors. Cancer Research, 74(4), 1214–1226.

[12]. Coleman, R. L., Lorusso, D., Gennigens, C., González-Martín, A., Randall, L., Cibula, D., Lund, B., Woelber, L., Pignata, S., Forget, F., Redondo, A., Vindeløv, S. D., Chen, M., Harris, J. R., Smith, M., Nicacio, L. V., Teng, M. S., Laenen, A., Rangwala, R., … Bhatia, S. (2021). Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovatv 204/GOG-3023/ENGOT-CX6): A multicentre, open-label, single-ARM, phase 2 study. The Lancet Oncology, 22(5), 609–619. https://doi.org/10.1016/s1470-2045(21)00056-5

Cite this article

Long,H.;Ma,B.;Shi,M.;Zeng,X. (2023). Drug Discovery and Development of Recently Approved Drugs: Tisotumab Vedotin. Theoretical and Natural Science,4,89-95.

Data availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

Disclaimer/Publisher's Note

The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

About volume

Volume title: Proceedings of the 2nd International Conference on Biological Engineering and Medical Science (ICBioMed 2022), Part II

ISBN：978-1-915371-27-0(Print) / 978-1-915371-28-7(Online)
Editor：Gary Royle, Steven M. Lipkin
Conference website: http://www.icbiomed.org
Conference date: 7 November 2022
Series: Theoretical and Natural Science
Volume number: Vol.4
ISSN：2753-8818(Print) / 2753-8826(Online)

© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open access policy for details).

References

[1]. McLachlan, J. et al. The Impact of Systemic Therapy Beyond First-line Treatment for Advanced Cervical Cancer. Clin. Oncol. 29, 153–160 (2017).

[2]. Hong, D. S. et al. Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer. Clin. Cancer Res. 26, 1220–1228 (2020).

[3]. Boussios, S. et al. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review. Crit. Rev. Oncol. Hematol. 108, 164–174 (2016).

[4]. Improved Survival with Bevacizumab in Advanced Cervical Cancer - PMC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010094/

[5]. Zamorano, A. S., Wan, L., Powell, M. A. & Massad, L. S. Repeating platinum/bevacizumab in recurrent or progressive cervical cancer yields marginal survival benefits. Gynecol. Oncol. Rep. 22, 48–51 (2017).

[6]. Eskander, R. N. & Tewari, K. S. Targeting angiogenesis in advanced cervical cancer. Ther. Adv. Med. Oncol. 6, 280–292 (2014).

[7]. Seagen Inc. A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer. https://clinicaltrials.gov/ct2/show/NCT03438396 (2022).

[8]. de Bono, J. S., Concin, N., Hong, D. S., Thistlethwaite, F. C., Machiels, J.-P., Arkenau, H.-T., Plummer, R., Jones, R. H., Nielsen, D., Windfeld, K., Ghatta, S., Slomovitz, B. M., Spicer, J. F., Yachnin, J., Ang, J. E., Mau-Sørensen, P. M., Forster, M. D., Collins, D., Dean, E., … Lassen, U. (2019). TISOTUMAB vedotin in patients with advanced or metastatic solid tumours (innovatv 201): A first-in-human, multicentre, phase 1–2 trial. The Lancet Oncology, 20(3), 383–393.

[9]. X, Z. et al. Expression of tissue factor in human cervical carcinoma tissue. Exp. Ther. Med. 16, (2018).

[10]. Tisotumab vedotin.Browsing drugs: Drugbank online. Browsing Drugs | DrugBank Online. (n.d.). Retrieved August 24, 2022, from https://go.drugbank.com/drugs

[11]. Breij, E. C. W., de Goeij, B. E. C. G., Verploegen, S., Schuurhuis, D. H., Amirkhosravi, A., Francis, J., Miller, V. B., Houtkamp, M., Bleeker, W. K., Satijn, D., & Parren, P. W. H. I. (2014). An antibody–drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors. Cancer Research, 74(4), 1214–1226.

[12]. Coleman, R. L., Lorusso, D., Gennigens, C., González-Martín, A., Randall, L., Cibula, D., Lund, B., Woelber, L., Pignata, S., Forget, F., Redondo, A., Vindeløv, S. D., Chen, M., Harris, J. R., Smith, M., Nicacio, L. V., Teng, M. S., Laenen, A., Rangwala, R., … Bhatia, S. (2021). Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovatv 204/GOG-3023/ENGOT-CX6): A multicentre, open-label, single-ARM, phase 2 study. The Lancet Oncology, 22(5), 609–619. https://doi.org/10.1016/s1470-2045(21)00056-5

For authors
Guide for authors Policies for authors Aims and scope Subscription Open access policy
For editors
Policies for editors Editorial board
For reviewers
Policies for reviewers Privacy policy

Cookies are used by this site.
Copyright © 2024 EWA Publishing, its licensors, and contributors. All rights reserved, including text and data mining, AI training, and similar technologies.